卡莫特罗

**卡莫特罗**
臨床資料
其他名稱	TA-2005; CHF-4226
给药途径	吸入
ATC碼	未分配;
法律規範狀態
法律規範	开发终止;
识别信息
	IUPAC命名法 8-Hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]-1H-quinolin-2-one; ;
CAS号	147568-66-9
PubChem CID	63952;
IUPHAR/BPS	7582;
ChemSpider	57545 ;
UNII	9810NUL4D1;
ChEMBL	ChEMBL1094785 ;
化学信息
化学式	C21H24N2O4
摩尔质量	368.43 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES C[C@H](CC1=CC=C(C=C1)OC)NC[C@@H](C2=C3C=CC(=O)NC3=C(C=C2)O)O;
	InChI InChI=1S/C21H24N2O4/c1-13(11-14-3-5-15(27-2)6-4-14)22-12-19(25)16-7-9-18(24)21-17(16)8-10-20(26)23-21/h3-10,13,19,22,24-25H,11-12H2,1-2H3,(H,23,26)/t13-,19+/m1/s1; Key:IHOXNOQMRZISPV-YJYMSZOUSA-N;

卡莫特罗（INN：carmoterol^[1]；开发代号：TA-2005和CHF-4226）.是一种非儿茶酚类^[2]实验性长效β肾上腺素受体激动剂（英语：Long-acting beta-adrenoceptor agonist）（ultra-LABA）^[2]^[3]，2010年之前曾进行过临床试验，但由于有证据表明该化合物不具有竞争性，因此不再进一步开发。^[4]

初步研究表明，在吸入3微克后，其作用持续时间超过24小时。^[2]该药物的药理学特征为其在离体豚鼠气管中的效力大于福莫特罗和沙美特罗。它对支气管肌肉的选择性是心肌组织的100多倍。^[5]

参考资料

^ International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53 (PDF). WHO Drug Information. 2005, 19 (1): 74 [25 March 2016].
^ ^2.0 ^2.1 ^2.2 Mario C, Monica K. 27. Bronchodilators: Beta2-Agonists and Anticholingercs. Clinical Asthma. Philadelphia, PA: Mosby / Elsevier Health Sciences. 2008. ISBN 978-0-323-04289-5.
^ Cazzola M, Calzetta L, Matera MG. β(2) -adrenoceptor agonists: current and future direction. British Journal of Pharmacology. May 2011, 163 (1): 4–17. PMC 3085864 . PMID 21232045. doi:10.1111/j.1476-5381.2011.01216.x.
^ Chiesi: Annual Report 2010 (PDF). Chiesi Farmaceutici S.p.A.: 20. [27 March 2016].
^ Donohue JF. New Options in COPD Therapy. Medscape. 2006 [27 March 2016].

这是一篇關於呼吸系統的藥理學小作品。你可以通过编辑或修订扩充其内容。

[1] International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 53 (PDF). WHO Drug Information. 2005, 19 (1): 74 [25 March 2016].

[Castro-2] 2.0 ^2.1 ^2.2 Mario C, Monica K. 27. Bronchodilators: Beta2-Agonists and Anticholingercs. Clinical Asthma. Philadelphia, PA: Mosby / Elsevier Health Sciences. 2008. ISBN 978-0-323-04289-5.

[3] Cazzola M, Calzetta L, Matera MG. β(2) -adrenoceptor agonists: current and future direction. British Journal of Pharmacology. May 2011, 163 (1): 4–17. PMC 3085864 . PMID 21232045. doi:10.1111/j.1476-5381.2011.01216.x.

[4] Chiesi: Annual Report 2010 (PDF). Chiesi Farmaceutici S.p.A.: 20. [27 March 2016].

[5] Donohue JF. New Options in COPD Therapy. Medscape. 2006 [27 March 2016].

[1]

[2]

[3]

[4]

[5]